文献速递药物相互作用药物不良反应与药物警戒

克唑替尼与索磷布韦/维帕他韦药代动力学相互作用致心脏毒性一例

Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.
PubMed 文献 · Br J Clin Pharmacol · 2023-02-08

本文报告一例75岁转移性非小细胞肺癌(MET外显子14跳跃突变)合并丙型肝炎病毒1A型感染患者,同时接受克唑替尼与索磷布韦/维帕他韦治疗。克唑替尼耐受良好,但启动索磷布韦/维帕他韦1周后出现双下肢水肿及NYHA III级呼吸困难。按Naranjo量表因果关系评定为很可能,推测克唑替尼暴露增加导致心脏毒性,机制涉及CYP3A4和P-糖蛋白的相互抑制作用。

要点

  • 克唑替尼与索磷布韦/维帕他韦联用可能增加克唑替尼暴露并引发心脏毒性。
  • 联用后出现双下肢水肿和NYHA III级呼吸困难应警惕药代动力学相互作用。
  • 抑制CYP3A4和/或P-gp的直接抗病毒药与克唑替尼等酪氨酸激酶抑制剂联用需谨慎。

核心结论

  • 克唑替尼与索磷布韦/维帕他韦之间可能存在药代动力学相互作用,导致克唑替尼暴露增加并引起心脏毒性。

研究设计与样本

  • 个案报道:1例75岁男性转移性非小细胞肺癌(MET外显子14缺失)合并丙型肝炎病毒1A型感染患者。

主要发现

  • 克唑替尼单药治疗耐受良好,但加用索磷布韦/维帕他韦1周后出现双下肢水肿和NYHA III级呼吸困难。
  • 按Naranjo量表评定,药物因果关系为很可能。
  • 推测克唑替尼与维帕他韦经CYP3A4和P-糖蛋白介导相互影响,导致克唑替尼暴露增加。

临床怎么用

  • 临床应警惕抑制CYP3A4(如格卡瑞韦)和/或P-gp(如伏西瑞韦、维帕他韦)的直接抗病毒药与主要经CYP3A4和/或P-gp代谢的酪氨酸激酶抑制剂(吉非替尼、阿法替尼、厄洛替尼、克唑替尼、色瑞替尼、劳拉替尼、布格替尼、卡马替尼等)联用的相互作用风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity. A 75-year-old man, with no cardiovascular history but a diagnosis of metastatic nonsmall cell lung cancer with mesenchymal-epithelial transition exon-14 deletion and hepatitis C virus infection genotype 1A, received both crizotinib and sofosbuvir/velpatasvir. Crizotinib was well tolerated, but 1 week after sofosbuvir/velpatasvir initiation, the patient experienced bilateral lower-limb oedema and class III New York Heart Association dyspnoea. We assumed that increased exposure to crizotinib could account for this cardiac toxicity. Drug causality was probable according to the Naranjo scale. We hypothesized a reciprocal interaction between crizotinib and velpatasvir, mediated by both cytochrome 3A4 (CYP3A4) and P-glycoprotein (P-gp). Clinicians should be aware of the risk of drug-drug interactions between direct-acting antiviral agents that inhibit CYP3A4 (glecaprevir) and/or P-gp (voxilaprevir, velpatasvir) and anticancer tyrosine kinase inhibitors that are mostly CYP3A4 and/or P-gp substrates (gefitinib, afatinib, erlotinib, crizotinib, ceritinib, lorlatinib, brigatinib, capmatinib etc.).

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Monribot A, Huillard O, Khoudour N, et al. Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. Br J Clin Pharmacol. 2023. PMID: 36709977. doi:10.1111/bcp.15674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。